Trials / Withdrawn
WithdrawnNCT00095017
Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)
A 4 Week Randomized, Placebo-Controlled, Parallel Group, Double-Blind Pilot Study to Assess the Safety and Efficacy of Etoricoxib 90 mg Versus Placebo in the Treatment of Cancer Pain
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effectiveness of an investigational drug versus placebo in the treatment of metastatic bone cancer pain in patients diagnosed with breast or prostate cancer and a bone neoplasm. Patients in the study will be taking opioids to treat moderate to severe pain for their bone metastases and will remain on their opioids during the entire course of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0663, etoricoxib / Duration of Treatment: 4 weeks |
Timeline
- Start date
- 2004-11-01
- First posted
- 2004-11-01
- Last updated
- 2022-02-16
Source: ClinicalTrials.gov record NCT00095017. Inclusion in this directory is not an endorsement.